Green tea and ACV are not 'nature's Ozempic,' full stop
Quick answer
The creator recommends daily consumption of diluted apple cider vinegar and green tea as a substitute for GLP-1 receptor agonist medications, claiming insulin-balancing and weight loss effects. While acetic acid has shown small effects on postprandial glucose in limited trials, neither ingredient replicates the mechanism of action of GLP-1 agonists, which operate through gut-hormone signaling pathways affecting appetite and gastric motility. Patients with insulin resistance, prediabetes, or obesity should consult a licensed provider before substituting evidence-based pharmacotherapy with dietary supplements.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team· This is not a transcript. It is our independent review of the video above.
What did @teshhxo actually say?
The creator claimed that apple cider vinegar (ACV) diluted in hot water, drunk every morning on an empty stomach, will "help balance your insulin levels," fix bloating, and aid weight loss. She also credited green tea with antioxidant properties and digestive benefits, recommending two to three cups daily. Then came the caption: she calls this combo her "nature's ozempic." That framing is doing a lot of heavy lifting, and it deserves a close look.
To her credit, she did say users should stay in a calorie deficit and exercise. She also gave a legitimate safety warning about not taking undiluted ACV shots due to esophageal damage risk. Those two points are actually solid. The rest needs unpacking.
Does the science back this up?
Partially, but not in the way the video implies. The insulin claim for ACV has some real evidence behind it, just not as dramatic as she suggests. A small 2004 study by Johnston et al. in Diabetes Care found that acetic acid (the active compound in ACV) reduced postprandial insulin response in insulin-resistant subjects. A 2019 meta-analysis by Hadi et al. in Diabetes Research and Clinical Practice found modest reductions in fasting blood glucose with ACV supplementation, but effect sizes were small and most trials had fewer than 30 participants.
For green tea, the evidence on weight loss is similarly underwhelming at scale. A 2012 Cochrane review by Jurgens et al. found that green tea preparations caused small, statistically non-significant weight loss in overweight adults. The catechin EGCG does show thermogenic activity in some trials, but the real-world effect on body weight is measured in fractions of a kilogram over months.
Calling any of this "nature's ozempic" is not accurate. GLP-1 receptor agonists like semaglutide work by mimicking a gut hormone that directly suppresses appetite, slows gastric emptying, and acts on brain receptors. ACV and green tea do not replicate that mechanism. There is no peer-reviewed evidence suggesting they come close.
What did they get wrong (or right)?
Wrong: The "nature's ozempic" framing is the biggest problem here. Comparing ACV and green tea to a prescription medication used to treat type 2 diabetes and obesity is misleading to anyone who might be weighing actual treatment options. People with metabolic conditions should not be swapping clinically validated medications for kitchen pantry ingredients based on TikTok captions.
Also questionable: the claim that one capful of diluted ACV will "genuinely solve" bloating. Bloating has many causes, including SIBO, IBS, food intolerances, and motility disorders. A blanket fix-all claim is not supported by evidence.
Right: Diluting ACV is genuinely important safety advice. A 2012 case report in the Journal of the American Dietetic Association documented esophageal injury from undiluted ACV consumption. She got that right, and it is worth saying so. She also correctly noted that weight loss still requires a calorie deficit, which is more honest than many creators in this space.
What should you actually know?
ACV and green tea are not dangerous for most healthy adults when used as described here. They may offer modest metabolic benefits at the margins. But the gap between "modest benefit at the margins" and "nature's ozempic" is enormous, and filling that gap with confidence is how people delay or avoid care that could actually help them.
If you are managing insulin resistance, prediabetes, or obesity, those conditions respond to interventions that have been tested in large randomized controlled trials, not two-ingredient morning routines. Semaglutide, for example, produced an average weight loss of about 15 percent of body weight over 68 weeks in the STEP 1 trial (Wilding et al., 2021, New England Journal of Medicine). No study on ACV or green tea comes close to those outcomes.
The advice to "do your own research and try it for yourself" sounds empowering but can be genuinely harmful when applied to health conditions that need clinical evaluation. Research on your own is fine. Replacing a provider conversation with a TikTok experiment is not.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Compounded Semaglutide access requires the right clinical path
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 7 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For Green tea and ACV are not 'nature's Ozempic,' full stop, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Primary STEP 1 trial source for semaglutide weight-management efficacy and adverse-event context.
PubMed
Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance
Used for maintenance, discontinuation, and weight-regain discussions after semaglutide response.
PubMed
Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference
A broad meta-analysis anchor for GLP-1 weight-loss effect and class-level comparisons.
PubMed
Discontinuing glucagon-like peptide-1 receptor agonists and body habitus
Used for pages discussing stopping therapy, weight regain, and long-term planning.
PubMed
Video claim decision path
Turn the claim into a safer next question
Direct answer
Compounded Semaglutide should be treated as a claim to verify, then compared with evidence, safety context, and a provider review path.
Evidence check
Social clips are useful prompts, but they rarely show the full evidence base, contraindications, or dosing context.
Safety check
A viral claim can miss patient-specific risks, medication interactions, legal access, and source quality.
Next step
Use the health tools and supporting evidence to prepare questions for your clinician.
Claim path
Keep researching this semaglutide video claims cluster
Best for searchers comparing social semaglutide claims with GLP-1 eligibility, outcomes, and safety context.
Claim verdict
The useful answer behind this video
Claim being checked
The creator recommends daily consumption of diluted apple cider vinegar and green tea as a substitute for GLP-1 receptor agonist medications, claiming insulin-balancing and weight loss effects.
FormBlends verdict
The creator recommends daily consumption of diluted apple cider vinegar and green tea as a substitute for GLP-1 receptor agonist medications, claiming insulin-balancing and weight loss effects. While acetic acid has shown small effects on postprandial glucose in limited trials, neither ingredient replicates the mechanism of action of GLP-1 agonists, which operate through gut-hormone signaling pathways affecting appetite and gastric motility. Patients with insulin resistance, prediabetes, or obesity should consult a licensed provider before substituting evidence-based pharmacotherapy with dietary supplements.
Patient-safe next step
Compare the claim with the Compounded Semaglutide guide, safety notes, access rules, and a licensed-provider review.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- The creator recommends daily consumption of diluted apple cider vinegar and green tea as a substitute for GLP-1 receptor agonist medications, claiming insulin-balancing and weight loss effects. While acetic acid has shown small effects on postprandial glucose in limited trials, neither ingredient replicates the mechanism of action of GLP-1 agonists, which operate through gut-hormone signaling pathways affecting appetite and gastric motility. Patients with insulin resistance, prediabetes, or obesity should consult a licensed provider before substituting evidence-based pharmacotherapy with dietary supplements.
- A 2019 meta-analysis (Hadi et al., Diabetes Research and Clinical Practice) found ACV produced only modest reductions in fasting blood glucose, with most source trials involving fewer than 30 participants.
- The STEP 1 trial showed semaglutide produced roughly 15 percent average body weight reduction over 68 weeks (Wilding et al., 2021, NEJM); no ACV or green tea trial approaches that outcome.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compounded Semaglutide decisions still need source quality, legal access, and provider oversight checks.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against the Compounded Semaglutide guide, cost path, safety notes, and provider review before acting.
Review Compounded SemaglutideWhat You'll Learn
- A 2019 meta-analysis (Hadi et al., Diabetes Research and Clinical Practice) found ACV produced only modest reductions in fasting blood glucose, with most source trials involving fewer than 30 participants.
- The STEP 1 trial showed semaglutide produced roughly 15 percent average body weight reduction over 68 weeks (Wilding et al., 2021, NEJM); no ACV or green tea trial approaches that outcome.
- A Cochrane review of green tea preparations for weight loss found effects that were small and not statistically significant in overweight adults (Jurgens et al., 2012).
- Undiluted ACV poses a real risk: case reports document esophageal mucosal damage from direct contact with acetic acid, so the dilution advice in this video is genuinely correct.
- Calling this combination 'nature's ozempic' is not supported by any mechanism or outcome data; GLP-1 agonists work through gut-hormone receptor pathways that dietary acids do not activate.
- Bloating has clinical causes ranging from IBS to SIBO to food intolerances; a single dietary ingredient is not a reliable or evidence-based treatment for all of them.
- Encouraging viewers to 'try it for yourself' instead of consulting a provider is fine for low-risk habits, but not appropriate framing when the comparison point is a prescription medication for metabolic disease.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
Tesh · TikTok creator
807.1K views on this video
My nature’s ozempic is green tea and acv .I drink it on a empty stomach. Thank me later 🤝 #greentea #applecidervinegarchallenge #acvweightlossdrink #3ballerinaherbaltea #smoothmoves #teaforhealth #fatlosstipsforwomen #supplementsthatwork
Sources & references
Citations extracted from our medical team's review. Click any citation to search PubMed.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by Tesh, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.